Clin2
NCT06356272Possibly a fitRecruiting

Oropharynx cancer biomarker study

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Metastatic Oropharyngeal Squamous Cell CarcinomaOropharyngeal Squamous Cell CarcinomaRecurrent Oropharyngeal Squamous Cell CarcinomaStage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8Head and Neck Carcinoma

Part of Cancer, Ear, nose & throat, Hormones & metabolism, Mouth & dental clinical trials.

This study looks at certain markers (called p16 and HPV) in tumor samples to better understand oropharynx cancer. It may help doctors learn more about the disease and guide future treatments.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
560 people
Ages
18 years and older
Study type
Observational

Who can take part

  • You must be 18 years or older.
  • You must be able to give written consent.
  • You must have a biopsy or surgery sample to test for p16 and HPV (unless the sample is too small).
  • You must be willing to come back to the clinic for follow-up visits at least 3 times, including before treatment.
  • You cannot be on any other experimental treatment for your cancer.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT04564989Recruiting
Biomarker study for HPV-related throat cancer outcomes

This observational study checks how well a blood test for HPV DNA (and other tumor genetic markers) predicts outcomes in certain throat cancers. It may help doctors better track the disease and plan treatment, because the trial validates these lab signals against real-world results.

Rochester, Minnesota
NCT05522881Recruiting
Study of genetic changes in oropharyngeal cancer tumors

This study collects information and tumor tissue to look for genetic changes in oropharyngeal cancer, especially in patients whose cancer has come back. The goal is to better understand the disease and may help future treatment planning.

Kaohsiung City
NCT05541016Recruiting· Phase 2
Personalized lower-dose radiation for HPV-related throat cancer

This Phase 2 study tests whether giving a less intense (de-escalated) radiation plan can work for certain people with HPV-related oropharyngeal throat cancer. It uses HPV blood testing and scans to help guide treatment, aiming to keep cancer control while reducing treatment side effects.

Scottsdale, Arizona
NCT04900623Recruiting· Phase 2
Using HPV blood test to guide treatment for HPV throat cancer

This Phase 2 study tests a “risk-adapted” treatment plan for HPV-related throat cancer, using an HPV DNA blood test to help decide how treatment is done. If your baseline blood test shows detectable HPV DNA, the study may help tailor therapy to your risk and potentially improve outcomes while limiting unnecessary treatment.

Boston, Massachusetts
NCT06323460Recruiting· Phase 2
Less Radiation for HPV Throat Cancer Guided by a Blood Test

This study tests a way to use less radiation for HPV-related throat cancer. Doctors will adjust your treatment based on a simple blood test that tracks cancer DNA, so you may get only the treatment you need.

Columbus, Ohio
NCT06007092Recruiting· Phase 1/Phase 2
HPV vaccine trial for oropharyngeal cancer patients

This trial tests a therapeutic vaccine for people with HPV16-positive oropharyngeal cancer who have finished curative treatment and are free of disease. The vaccine aims to help the immune system prevent the cancer from coming back.

Villejuif

Hear when a new Metastatic Oropharyngeal Squamous Cell Carcinoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.